Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
1.98
+0.03 (1.54%)
After Hours: 2.00 +0.02 (1.01%)
Nov 22, 7:29PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.93 - 2.00
52 week 1.74 - 3.15
Open 1.96
Vol / Avg. 667,344.00/1.45M
Mkt cap 315.28M
P/E     -
Div/yield     -
EPS -0.18
Shares 159.23M
Beta 2.66
Inst. own 39%
Nov 28, 2017
Geron Corp at Piper Jaffray Healthcare Conference - 3:30PM EST - Add to calendar
Nov 14, 2017
Geron Corp at Stifel Healthcare Conference
Nov 1, 2017
Q3 2017 Geron Corp Earnings Call - Webcast
Sep 26, 2017
Geron Corp at Cantor Fitzgerald Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -4232.52% -479.34%
Operating margin -4444.17% -497.34%
EBITD margin - -496.02%
Return on average assets -23.20% -21.17%
Return on average equity -25.01% -22.33%
Employees 15 -
CDP Score - -

Address

149 Commonwealth Dr Ste 2070
MENLO PARK, CA 94025-1133
United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

Officers and directors

Hoyoung Huh Ph.D. Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 46
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 62
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Development and Technical Operations
Age: 50
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Business Development and Portfolio and Alliance Management
Age: 51
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Daniel M. Bradbury Independent Director
Age: 56
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr. Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters